The results showed that PR1 peptide vaccine can induce specific immunity reaction and related clinical reactions in MDS patients including molecular remission and no adverse autoimmunity symptoms, which finally lead to the increase of PR1-CTL in circulating (118). This evidence concerns the gene TMEM37 and myelodysplastic syndrome.